FDMT — 4D MOLECULAR THERAPEUTICS ORD share price
Last Trade - 00:00- $665.17m
- $405.30m
- $13.61m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 5.79 | 14.13 | 6.99 | 13.61 | 3.6 | 3.55 | 32.97% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Latest News for FDMT
Upcoming events for FDMT
Similar to FDMT
4D MOLECULAR THERAPEUTICS ORD
NASDAQ Global Select Market
ABCELLERA BIOLOGICS ORD
NASDAQ Global Select Market
ABSCI ORD
NASDAQ Global Select Market
ACADIA PHARMACEUTICALS ORD
NASDAQ Global Select Market
ACHILLES THERAPEUTICS ADS
NASDAQ Global Select Market
ACLARIS THERAPEUTICS ORD
NASDAQ Global Select Market
ACUMEN PHARMACEUTICALS ORD
NASDAQ Global Select Market
ALIGOS THERAPEUTICS ORD
NASDAQ Global Select Market
ALKERMES ORD
NASDAQ Global Select Market
ALNYLAM PHARMACEUTICALS ORD
NASDAQ Global Select Market
ANGION BIOMEDICA ORD
NASDAQ Global Select Market
APPLIED MOLECULAR TRANSPORT ORD
NASDAQ Global Select Market
APREA THERAPEUTICS ORD
NASDAQ Global Select Market
ARENA PHARMACEUTICALS ORD
NASDAQ Global Select Market
ATHIRA PHARMA ORD
NASDAQ Global Select Market
BEAM THERAPEUTICS ORD
NASDAQ Global Select Market
BICYCLE THERAPEUTICS ADR
NASDAQ Global Select Market
BIOMEA FUSION ORD
NASDAQ Global Select Market
BIO TECHNE ORD
NASDAQ Global Select Market
BLUEPRINT MEDICINES ORD
NASDAQ Global Select Market
FAQ
As of Today at 16:51 UTC, shares in 4D MOLECULAR THERAPEUTICS ORD are trading at $24.87, giving the company a market capitalisation of $665.17m. This share price information is delayed by 15 minutes.
Shares in 4D MOLECULAR THERAPEUTICS ORD are currently trading at $24.87 and the price has moved by over the past 365 days. In terms of relative price strength the 4D MOLECULAR THERAPEUTICS ORD share price has matched the S&P500 Index by over the past year.
The overall consensus recommendation for 4D MOLECULAR THERAPEUTICS ORD is Buy. You can view the full broker recommendation list by unlocking its StockReport.
4D MOLECULAR THERAPEUTICS ORD does not currently pay a dividend.
4D MOLECULAR THERAPEUTICS ORD does not currently pay a dividend.
4D MOLECULAR THERAPEUTICS ORD does not currently pay a dividend.
To buy shares in 4D MOLECULAR THERAPEUTICS ORD you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in 4D MOLECULAR THERAPEUTICS ORD are currently trading at $24.87, giving the company a market capitalisation of $665.17m.
Here are the trading details for 4D MOLECULAR THERAPEUTICS ORD:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: FDMT
Based on an overall assessment of its quality, value and momentum 4D MOLECULAR THERAPEUTICS ORD is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in 4D MOLECULAR THERAPEUTICS ORD is $52.33. That is 110.41% above the current share price of $24.87.
Analysts covering 4D MOLECULAR THERAPEUTICS ORD currently have a consensus Earnings Per Share (EPS) forecast of -$2.84 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Relative Strength is an often used as a momentum indicator. Price trends tend to persist, so it's worth looking at them when it comes to a share like 4D MOLECULAR THERAPEUTICS ORD. Over the past six months, its share price has underperformed the S&P500 Index by -49.59%.
At the current price of $24.87, shares in 4D MOLECULAR THERAPEUTICS ORD are trading -30.78% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for 4D MOLECULAR THERAPEUTICS ORD.
We do not have data on 4D MOLECULAR THERAPEUTICS ORD's directors
We do not have data on 4D MOLECULAR THERAPEUTICS ORD's shareholders